Pharmaceutical Effect of Manganese Porphyrins on Manganese Superoxide Dismutase Deficient Mice

详细信息    查看全文

• 作者：Natsumi Hayakawa ; Shoichiro Asayama ; Yoshihiro Noda ; Takahiko Shimizu ; Hiroyoshi Kawakami
• 刊名：Molecular Pharmaceutics
• 出版年：2012
• 出版时间：October 1, 2012
• 年：2012
• 卷：9
• 期：10
• 页码：2956-2959
• 全文大小：210K
• 年卷期：v.9,no.10(October 1, 2012)
• ISSN：1543-8392

文摘

Mice lacking manganese-superoxide dismutase (Mn-SOD) activity exhibit typical pathology of dilated cardiomyopathy (DCM). In the present study, the structure鈥揳ctivity relationship between the water-soluble manganese (Mn) porphyrin with SOD activity and the in vivo pharmaceutical effect on DCM is reported. The Mn-SOD-deficient mice were treated with Mn-porphyrins for 3 weeks. The treatment of a Mn-porphyrin, MnM2Py₂P, suppressed the progression of cardiac dilation. These results suggest that the Mn-porphyrin MnM2Py₂P treatment is proposed as a potential therapy for DCM.

Keywords:

water-soluble manganese porphyrin; superoxide dismutase mimic; manganese superoxide dismutase deficient mice; dilated cardiomyopathy; antioxidative therapy